Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment2020 · 49 citations
2. 2Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype2025 · 11 citations
3. 3PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy2024 · 92 citations
4. 4Increased co-expression of 4-1BB with PD-1 on CD8+ tumor-infiltrating lymphocytes is associated with improved prognosis and immunotherapy response in cervical cancer2024 · 2 citations
5. 5Differential signaling through the PD-1 receptor allows for a distinct inhibitory signature and unique signal dichotomy between PD-L1 and PD-L2 22610442026